Abstract
Hyperechogenicity of the substantia nigra (SN) has been found to be a typical sign in idiopathic Parkinson's disease (PD), prevalent in more than 90% of affected individuals. To see whether SN hyperechogenicity is also characteristic for monogenetically caused PD, we investigated PD patients with alpha-synuclein, LRRK2, parkin, PINK1 and DJ-1 mutations by transcranial sonography (TCS). In all these patients the area of SN echogenicity was significantly larger than in healthy controls, but smaller, than in idiopathic PD. As SN hyperechogenicity could be related to an increased iron content of the SN, these findings suggest that iron may play a less significant role in the pathogenesis of monogenetically caused compared to idiopathic PD.
Similar content being viewed by others
References
Berg D, Gerlach M, Youdim M, Double K, Zecca L, Riederer P, Becker G (2001) Brain iron pathways and their relevance to Parkinson's disease. J Neurochem 79:225-36
Berg D, Merz B, Reiners K, Naumann M, Becker G (2005) Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov Disord 20:383-85
Berg D, Roggendorf W, Schroder U, Klein R, Tatschner T, Benz P, Tucha O, Preier M, Lange KW, Reiners K, Gerlach M, Becker G (2002) Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59:999-005
Berg D, Siefker C, Becker G (2001) Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol 248:684-89
Bonifati V, Rohe CF, Breedveld GJ, Fabrizio E, De Mari M, Tassorelli C, Tavella A, Marconi R, Nicholl DJ, Chien HF, Fincati E, Abbruzzese G, Marini P, De Gaetano A, Horstink MW, Maat- Kievit JA, Sampaio C, Antonini A, Stocchi F, Montagna P, Toni V, Guidi M, Dalla Libera A, Tinazzi M, De Pandis F, Fabbrini G, Goldwurm S, de Klein A, Barbosa E, Lopiano L, Martignoni E, Lamberti P, Vanacore N, Meco G, Oostra BA (2005) Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 65:87-5
Clark LN, Afridi S, Karlins E, Wang Y, Mejia-Santana H, Harris J, Louis ED, Cote LJ, Andrews H, Fahn S, Waters C, Ford B, Frucht S, Ottman R, Marder K (2006) Case-control study of the parkin gene in early-onset Parkinson disease. Arch Neurol 63:548-52
Dawson TM, Dawson VL (2003) Molecular pathways of neurodegeneration in Parkinson's disease. Science 302:819-22
Dexter D, Sian J, Jenner P, Marsden C (1993) Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia. Adv Neurol 60:273-81
Hallgren B, Sourander P (1958) The effect of age on the non-haemin iron in the human brain. J Neurochem 3:41-1
Hashimoto M, Rockenstein E, Masliah E (2003) Transgenic models of alphasynuclein pathology: past, present, and future. Ann N Y Acad Sci 991:171-88
Hering R, Strauss KM, Tao X, Bauer A, Woitalla D, Mietz EM, Petrovic S, Bauer P, Schaible W, Muller T, Schols L, Klein C, Berg D, Meyer PT, Schulz JB, Wollnik B, Tong L, Kruger R, Riess O (2004) Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7). Hum Mutat 24:321-29
Hochstrasser H, Bauer P, Walter U, Behnke S, Spiegel J, Csoti I, Zeiler B, Bornemann A, Pahnke J, Becker G, Riess O, Berg D (2004) Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 63:1912-917
Jimenez Del Rio M, Moreno S, Garcia- Ospina G, Buritica O, Uribe CS, Lopera F, Velez-Pardo C (2004) Autosomal recessive juvenile parkinsonism Cys212Tyr mutation in parkin renders lymphocytes susceptible to dopamineand iron-mediated apoptosis. Mov Disord 19:324-30
Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W, Bart J, Willemsen AT, Hendrikse NH (2005) Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 57:176-79
Kruger R, Kuhn W, Leenders KL, Sprengelmeyer R, Muller T, Woitalla D, Portman AT, Maguire RP, Veenma L, Schroder U, Schols L, Epplen JT, Riess OHP (2001) Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. Neurology 22;56(10):1355-362
Schlitter AM, Kurz M, Larsen JP, Woitalla D, Muller T, Epplen JT, Dekomien G (2006) Parkin gene variations in late-onset Parkinson's disease: comparison between Norwegian and German cohorts. Acta Neurol Scand 113:9-3
Walter U, Klein C, Hilker R, Benecke R, Pramstaller PP, Dressler D (2004) Brain parenchyma sonography detects preclinical parkinsonism. Mov Disord 19:1445-449
Wang C, Ko HS, Thomas B, Tsang F, Chew KC, Tay SP, Ho MW, Lim TM, Soong TW, Pletnikova O, Troncoso J, Dawson VL, Dawson TM, Lim KL (2005) Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Hum Mol Genet 14:3885-897
Wolozin B, Golts N (2002) Iron and Parkinson's disease. Neuroscientist 8:22-2
Zecca L, Berg D, Arzberger T, Ruprecht P, Rausch WD, Musicco M, Tampellini D, Riederer P, Gerlach M, Becker G (2005) In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord 20:1278-285
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schweitzer, K.J., Brüssel, T., Leitner, P. et al. Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease. J Neurol 254, 613–616 (2007). https://doi.org/10.1007/s00415-006-0369-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-006-0369-7